Primary information |
---|
ID | antitb_1354, |
Name | 10585872 |
N-Terminal modification | Nk-lysin |
C-Terminal Modification | NEDTVTQAASRVCDKMKILRGVCKKIMRTFLRRISKD |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | Internal disuphide bond 13 -23 |
Chirality | Cyclic |
Nature | 37 |
Source | L |
Species | Natural |
Strain | Pig cytolytic lymphocytes |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv ATCC 25618 |
Cell Line | IC90 = 30 μM |
Inhibition Concentration | In vitro |
Sequence | 1999 |
Cytotoxicity | Human erythroleukaemia cell line K562 |
In vivo Model | NA |
Lethal Dose | 30 % cytolytic activity in range of 3 -7 μM peptide concentration |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | NA |
Other activities | NA |
PMID | NA |
Year of Publication | Antibacterial against bacillus megaterium, E.coli, P.aeuroginosaand S.aureus |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1524, |
Name | 25681127 |
N-Terminal modification | NK-Lysin |
C-Terminal Modification | NEDTVTQAASRVCDKMKILRGVCKKIMRTFLRRISKD |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 36 |
Source | L |
Origin | Cationic |
Species | Synthetic |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
Cell Line | Reduction in bacterial growth inhibiton to 60% at conc. Of 9.37 mg/L |
Inhibition Concentration | in vitro |
Sequence | 2015 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | NA |
Combination Therapy | Inteacting with microbial membrane |
Other activities | NA |
PMID | NA |
Year of Publication | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas |
Tertiary Structure (Technique) | Not Predicted), |